A Polymorphism in the Complement ComponentC1qACorrelates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Lists
Only you see this
Abstract
Our findings indicate that polymorphisms in the C1qA gene may affect the clinical response and duration of response to rituximab therapy of follicular lymphoma. These results could have direct implications on designing antibodies with improved efficiency and enhance our understanding of the role of complement in monoclonal antibody therapy.
BibTeX
@inproceedings{racila2008polymorphism,
author = {Emilian Racila and Brian K. Link and Wen‐Kai Weng and Thomas E. Witzig and Stephen M. Ansell and Matthew J. Maurer and Jian Huang and Christopher E. Dahle and Ahmad Halwani and Ronald Levy and George J. Weiner},
title = {{A Polymorphism in the Complement Component<i>C1qA</i>Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma}},
booktitle = {Clinical},
year = {2008},
doi = {10.1158/1078-0432.ccr-08-0745},
}Loading related content...